The Clorox Company manufactures and markets consumer and professional products worldwide. Valued at $11.72B, CLX is a large-cap name in its sector. The company operates through four segments: Health and Wellness, Household, Lifestyle, and International.
Premium feature
News & analytics is part of Premium.
Every headline runs through our finance-grade sentiment engine, so you see the mood of the market on each ticker before you read a single article. Plus the full analyst consensus and target-price upside, refreshed daily.
Per-headline sentiment, scored by a finance-tuned model
See exactly where the price sits versus its 150-day moving average, the live RSI reading, MACD momentum, and volume context, for any ticker, every day.
The Clorox Company carries $4.49B in total debt against $1.19B in cash reserves — debt is roughly 3.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $62.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 546.1% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.0% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $7.11B (2022) to $7.10B (2025).
With a beta below 0.7, The Clorox Company typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLX.